throbber
CENTER FOR DRUG EVALUATION AND
`RESEARCH
`
`
`
`APPLICATION NUMBER:
`202107Orig1s000
`
`MEDICAL REVIEW(S)
`
`
`
`
`
`
`
`
`
`
`

`

`
`
`CLINICAL REVIEW
`
`Application Type NDA
`Application Number(s) 202107
`Priority or Standard Standard
`
`Submit Date(s)
`
`Received Date(s) April 18, 2011
`PDUFA Goal Date February 18, 2012
`Division / Office DMEP
`
`Reviewer Name(s) Zemskova Marina, MD
`Review Completion Date January 13, 2012
`
`Established Name Mifepristone
`(Proposed) Trade Name Korlym
`Therapeutic Class
`
`Applicant Corcept Therapeutics
`
`Formulation(s) Oral tablets
`Dosing Regimen 300-1200 mg once a day
`Indication(s) Endogenous Cushing’s
`syndrome
`Intended Population(s) Adults
`
`
`
`Template Version: March 6, 2009
`
`
`
`Reference ID: 3075278
`
`

`

`Clinical Review
`Marina Zemskova, M.D
`NDA 202107
` (Mifepristone Tablets)
`
`
`
`Table of Contents
`
`2
`
`1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT.............................................. 9
`1.1 Recommendation on Regulatory Action .......................................................................... 9
`1.2 Risk Benefit Assessment .................................................................................................. 9
`1.3 Recommendations for Postmarket Risk Evaluation and Mitigation Strategies.............. 14
`1.4 Recommendations for Postmarket Requirements and Commitments ............................ 15
`INTRODUCTION AND REGULATORY BACKGROUND.......................................... 15
`2.1 Product Information........................................................................................................ 15
`2.2 Tables of Currently Available Treatments for Proposed Indications............................. 16
`2.3 Availability of Proposed Active Ingredient in the United States ................................... 18
`2.4
`Important Safety Issues With Consideration to Related Drugs...................................... 18
`2.5 Summary of Presubmission Regulatory Activity Related to Submission ...................... 19
`2.6 Other Relevant Background Information ....................................................................... 22
`3 ETHICS AND GOOD CLINICAL PRACTICES ............................................................ 22
`3.1 Submission Quality and Integrity................................................................................... 22
`3.2 Compliance with Good Clinical Practices...................................................................... 22
`3.3 Financial Disclosures...................................................................................................... 24
`4 SIGNIFICANT EFFICACY/SAFETY ISSUES RELATED TO OTHER REVIEW
`DISCIPLINES...................................................................................................................... 24
`4.1 Chemistry Manufacturing and Controls ......................................................................... 24
`4.2 Clinical Microbiology..................................................................................................... 25
`4.3 Preclinical Pharmacology/Toxicology ........................................................................... 25
`4.4 Clinical Pharmacology ................................................................................................... 26
`4.4.1 Mechanism of Action .............................................................................................. 26
`4.4.2
`Pharmacodynamics.................................................................................................. 27
`4.4.3
`Pharmacokinetics..................................................................................................... 27
`5 SOURCES OF CLINICAL DATA..................................................................................... 31
`5.1 Tables of Studies/Clinical Trials .................................................................................... 31
`5.2 Review Strategy.............................................................................................................. 35
`5.3 Discussion of Individual Studies/Clinical Trials............................................................ 35
`5.3.1
`Study C1073-400 (Study 400)................................................................................. 35
`5.3.2
`Study C1073-415 (Study 415)................................................................................. 48
`5.3.3 Non-Cushing’s Corcept-sponsored studies.................................................................. 52
`6 REVIEW OF EFFICACY .................................................................................................. 62
`Efficacy Summary .................................................................................................................... 62
`6.1
`Indication........................................................................................................................ 62
`6.1.1 Methods................................................................................................................... 62
`6.1.2 Demographics.......................................................................................................... 62
`
`Reference ID: 3075278
`
`2
`
`(b) (4)
`
`

`

`Clinical Review
`Marina Zemskova, M.D
`NDA 202107
` (Mifepristone Tablets)
`
`
`
`Subject Disposition.................................................................................................. 70
`6.1.3
`6.1.4 Analysis of Primary Endpoint(s)............................................................................. 72
`6.1.5 Analysis of Secondary Endpoints(s) ....................................................................... 83
`6.1.6 Other Endpoints....................................................................................................... 90
`6.1.7
`Subpopulations ........................................................................................................ 96
`6.1.8 Analysis of Clinical Information Relevant to Dosing Recommendations .............. 97
`6.1.9 Discussion of Persistence of Efficacy and/or Tolerance Effects............................. 98
`6.1.10 Additional Efficacy Issues/Analyses....................................................................... 98
`7 REVIEW OF SAFETY ..................................................................................................... 102
`Safety Summary...................................................................................................................... 102
`7.1 Methods ........................................................................................................................ 102
`7.1.1
`Studies/Clinical Trials Used to Evaluate Safety.................................................... 103
`7.1.2 Categorization of Adverse Events......................................................................... 103
`7.1.3
`Pooling of Data across Studies/Clinical Trials to Estimate and Compare Incidence
`............................................................................................................................... 103
`7.2 Adequacy of Safety Assessments................................................................................. 103
`7.2.1 Overall Exposure at Appropriate Doses/Durations and Demographics of Target
`Populations ............................................................................................................ 104
`7.2.2 Explorations for Dose Response ........................................................................... 107
`7.2.3
`Special Animal and/or In Vitro Testing ................................................................ 109
`7.2.4 Routine Clinical Testing........................................................................................ 110
`7.2.5 Metabolic, Clearance, and Interaction Workup..................................................... 110
`7.2.6 Evaluation for Potential Adverse Events for Similar Drugs in Drug Class .......... 110
`7.3 Major Safety Results .................................................................................................... 110
`7.3.1 Deaths.................................................................................................................... 110
`7.3.2 Nonfatal Serious Adverse Events.......................................................................... 113
`7.3.3 Dropouts and/or Discontinuations......................................................................... 122
`7.3.4
`Significant Adverse Events ................................................................................... 126
`7.3.5
`Submission Specific Primary Safety Concerns..................................................... 126
`7.4 Supportive Safety Results............................................................................................. 151
`7.4.1 Common Adverse Events...................................................................................... 151
`7.4.2 Laboratory Findings .............................................................................................. 156
`7.4.3 Vital Signs ............................................................................................................. 167
`7.4.4 Electrocardiograms (ECGs) .................................................................................. 168
`7.4.5
`Special Safety Studies/Clinical Trials ................................................................... 169
`7.4.6
`Immunogenicity..................................................................................................... 175
`7.5 Other Safety Explorations ............................................................................................ 175
`7.5.1 Dose Dependency for Adverse Events.................................................................. 175
`7.5.2 Time Dependency for Adverse Events.................................................................. 175
`7.5.3 Drug-Demographic Interactions............................................................................ 177
`7.5.4 Drug-Disease Interactions ..................................................................................... 177
`7.5.5 Drug-Drug Interactions ......................................................................................... 178
`7.6 Additional Safety Evaluations...................................................................................... 180
`
`Reference ID: 3075278
`
`3
`
`(b) (4)
`
`

`

`Clinical Review
`Marina Zemskova, M.D
`NDA 202107
` (Mifepristone Tablets)
`
`
`
`7.6.1 Human Carcinogenicity......................................................................................... 180
`7.6.2 Human Reproduction and Pregnancy Data ........................................................... 180
`7.6.3
`Pediatrics and Assessment of Effects on Growth.................................................. 181
`7.6.4 Overdose, Drug Abuse Potential, Withdrawal and Rebound................................ 182
`7.7 Additional Submissions / Safety Issues........................................................................ 182
`7.7.1
`120-day safety update............................................................................................ 182
`7.7.2 Literature review........................................................................................................ 186
`8 POSTMARKET EXPERIENCE...................................................................................... 189
`9 APPENDICES.................................................................................................................... 190
`9.1 Literature Review/Reference........................................................................................ 190
`9.1.1 Literature Review....................................................................................................... 190
`9.1.2 References.................................................................................................................. 197
`9.2 Labeling Recommendations ......................................................................................... 200
`9.3 Advisory Committee Meeting......................................................................................... 200
`
`
`
`Reference ID: 3075278
`
`4
`
`(b) (4)
`
`

`

`Clinical Review
`Marina Zemskova, M.D
`NDA 202107
` (Mifepristone Tablets)
`
`
`
`Table of Tables
`
`Table 1. Adrenal-blocking Drugs ................................................................................................. 18
`Table 2. Research Sites for the DSI audition............................................................................... 22
`Table 3. Number (%) of Patients with Protocol Violations.......................................................... 24
`Table 4. Mifepristone Cmax and AUC following Single Doses of 300, 600, and 1200 mg in
`Healthy Adults in the Fasted State (Source: Table 44 Clinical Pharmacology Summary) .......... 28
`Table 5. Summary of Plasma PK Parameters of Mifepristone and its Metabolites following a
`Single dose of 600 mg or Multiple doses of 600 mg/day of Mifepristone for 7 days (Study C-
`1073-05)........................................................................................................................................ 29
`Table 6. Corcept’s Safety and Efficacy Studies in Patients with Cushing’s syndrome................ 31
`Table 7. Corcept's Clinical Studies in non-Cushing’s syndrome indication / patients................. 31
`Table 8. Korlym Dosing Regimen................................................................................................ 37
`Table 9. Patients Disposition and Reasons for the Withdrawal in Study 415 .............................. 52
`Table 10. Non-Cushing’s Corcept's Studies That Provided the Supportive Safety Data for
`Mifepristone.................................................................................................................................. 54
`Table 11. Demographics and Body Measurements at Baseline (ITT/Safety Population) ............ 63
`Table 12. Medical Therapy of Hypercortisolemia (ITT/Safety Population) ................................ 64
`Table 13. Cushing’s Syndrome History and Signs/Symptoms at Screening (Safety Population) 65
`Table 14. Summary of Subjects with > 80% Compliance with Study Drug by Analysis
`Population and Cohort .................................................................................................................. 67
`Table 15. Concomitant Medications Used by ≥ 20% or More of the Overall Study Population
`(ITT/Safety Population)................................................................................................................ 68
`Table 16. Concomitant Medications Used to Treat Diabetes (ITT/Safety Population)................ 69
`Table 17. Concomitant Medications Used to Treat Hypertension (ITT/Safety Population) ........ 70
`Table 18. Patient Disposition by Populations and Study Cohort (n (%)) ..................................... 71
`Table 19. Cumulative Distribution Function for Percent Reduction in AUCglucose at Week 24/ET
`in C-DM Subjects (mITT population) .......................................................................................... 74
`Table 20. Reduction in AUCglucose e in C-DM Subjects by Visit (mITT Population) .................. 76
`Table 21. Cumulative Distribution Function for Change in Diastolic Blood Pressure at Week
`24/ET in C-HT Subjects (mITT Population) ................................................................................ 78
`Table 22. Summary of Diastolic Blood Pressure in C-HT Subjects by Visit (mITT Population) 80
`Table 23. Diastolic Blood Pressure at Baseline and Week 24 Visit for Subjects with and without
`Spironolactone Treatment: C-HT Cohort mITT Population......................................................... 81
`Table 24. Systolic and Diastolic BP Changes and changes in dose and/or number of
`antihypertensive medications in C-HT cohort (mITT population)............................................... 83
`Table 25. HbA1C and % of AUCglucose Changes from Baseline to Week 24 Visit in Patients with
`Elevated HbA1C at Baseline in C-DM Cohort (mITT Population)............................................... 85
`Table 26. Reduction in Antidiabetic Medications (mITT Population)......................................... 86
`Table 27. Percent Change in Body Weight from Baseline to Week 24 (mITT Population) ........ 87
`Table 28. Summary of Change from Baseline in SBP: All Subjects with Hypertension at
`Screening (mITT population) ....................................................................................................... 88
`Table 29. Median Scores of Data Review Board for Clinical Improvement by Visit.................. 90
`Table 30. Summary of Changes from Baseline in AUCinsulin by Visit (Population)..................... 91
`
`Reference ID: 3075278
`
`5
`
`(b) (4)
`
`

`

`Clinical Review
`Marina Zemskova, M.D
`NDA 202107
` (Mifepristone Tablets)
`
`
`Table 31. Summary of HOMA-IR Results by Visit and Population (C-HT subjects and C-DM
`Subjects Not Taking Insulin) ........................................................................................................ 92
`Table 32. Summary of Change from Baseline in Waist Circumference (mITT Population) ....... 92
`Table 33. Summary of Change from Baseline in Body Composition by Visit............................. 93
`Table 34. Demographics and Disease characteristics in Patients Included in Published Reports of
`Mifepristone for the Treatment of Cushing's syndrome ............................................................... 99
`Table 35. Efficacy Observations during Mifepristone Treatment of Cushing's syndrome ........ 100
`Table 36. Demographic Characteristics in the Primary and Extension Studies (Study 400 and
`415) ............................................................................................................................................. 104
`Table 37. Extent of Exposure in Study 400 (ITT/Safety Population)......................................... 105
`Table 38. Extent of Cumulative Exposure (Study 400 and 415) ................................................ 106
`Table 39. Summary of TEAEs by Dose Levels in Safety population (Study 400) .................... 108
`Table 40. Listing of deaths in supportive Corcept’s studies in other indications....................... 112
`Table 41. Listing of SAEs in Patients Who Received Mifepristone in Non-Cushing’s Studies.121
`Table 42. Patients Disposition and Reasons for the Withdrawal in studies 400 and 415........... 122
`Table 43. Summary of AEs that Led to the Study Withdrawal in Non-Cushing’s Syndrome
`Studies......................................................................................................................................... 125
`Table 44. Summary of Subjects Who Experienced AI in Studies 400 and/or 415..................... 127
`Table 45. Summary of Subjects with Suspected AI, but Not Reported as AI in Study 400....... 128
`Table 46. Summary of Subjects Who Experienced Vaginal Bleeding in Studies 400 and/or 415
`..................................................................................................................................................... 131
`Table 47. Potassium Values and Korlym Doses in Subjects with Hypokalemia in Study 400 .. 135
`Table 48. Potassium Values and Korlym Doses in Subjects with Hypokalemia in Study 415 .. 137
`Table 49. Summary of Subjects with an Elevation in TSH in Study 400................................... 139
`Table 50. Summary of Subjects with an Elevation in TSH in Study 415................................... 139
`Table 51. ECG Intervals (Change from Screening to Day 14 Summary Statistics)................... 143
`Table 52. Summary of Subjects with QTcF ≥ 450 msec or an Increase in QTcF ≥ 30 msec
`(original NDA data) .................................................................................................................... 143
`Table 53. Listing of Subjects with QTcB ≥ 450 msec or a Change in QTcB ≥ 30 msec ........... 144
`Table 54. Summary of Treatment-emergent Adverse Events Occurring in > 5% Subjects in Study
`400............................................................................................................................................... 152
`Table 55. Treatment-emergent Adverse Events Occurring in Three (10%) or More Subjects by
`System Organ Class and Preferred Term (Safety Population) in Study 415 .............................. 155
`Table 56. Summary of Hematology Parameter Values (Study 400) .......................................... 158
`Table 57. Summary of Hematology Parameter Values (Study 415) .......................................... 160
`Table 58. Clinical Chemistry Parameter (Study 400)................................................................. 161
`Table 59. Clinical Chemistry Parameter (Study 415)................................................................. 163
`Table 60. Summary of Lipid Data (Study 400; Safety Population)............................................ 164
`Table 61. Summary of Lipids Values (Study 415) ..................................................................... 165
`Table 62. Summary Statistics for Vital Signs values (Study 415).............................................. 168
`Table 63. The Point Estimates and the 90% CIs Corresponding to the Largest Upper Bounds for
`mifepristone (600 mg and 1800 mg, Day 7) and the Largest Lower Bound for Moxifloxacin (Day
`14) (FDA Analysis)..................................................................................................................... 171
`
`Reference ID: 3075278
`
`6
`
`(b) (4)
`
`

`

`Clinical Review
`Marina Zemskova, M.D
`NDA 202107
` (Mifepristone Tablets)
`
`
`Table 64. Comparison of Treatment-emergent Adverse Events (Occurring in Three or More
`Subjects) Starting in Study 400 and Study 415 by System Organ Class and Preferred Term
`(Safety Population) ..................................................................................................................... 176
`Table 65. Mifepristone Doses Used in the Treatment of Patients with Cushing's syndrome..... 187
`Table 66. Safety Observations during Mifepristone Treatment of Cushing's syndrome............ 188
`
`
`Reference ID: 3075278
`
`7
`
`(b) (4)
`
`

`

`Clinical Review
`Marina Zemskova, M.D
`NDA 202107
` (Mifepristone Tablets)
`
`
`
`Table of Figures
`
`Figure 1. Structural Formula......................................................................................................... 15
`Figure 2. Cumulative Distribution Function for Percent Change in AUCglucose from Baseline to
`Week 24/ET: C-DM Cohort (mITT Population) .......................................................................... 74
`Figure 3. Plot of the Individual AUCglucose Values versus Time Profile (Responders in C-DM
`Cohort of mITT Population) ......................................................................................................... 75
`Figure 4. Plot of Mean AUCglucose values versus Time Profile (C-DM Cohort, mITT Population)
`....................................................................................................................................................... 76
`Figure 5. Cumulative Distribution Function for mm HG in DBP from Baseline to Week 24/ET:
`C-HT Cohort (mITT Population).................................................................................................. 78
`Figure 6. Mean DBP values Versus Time Profile: C-HT Cohort (mITT Population).................. 79
`Figure 7. Mean SBP values Versus Time Profile: All Patients with Hypertension at baseline
`(mITT Population) ........................................................................................................................ 88
`
`
`Reference ID: 3075278
`
`8
`
`(b) (4)
`
`

`

`Clinical Review
`Marina Zemskova, M.D
`NDA 202107
` (Mifepristone Tablets)
`
`
`
`1 Recommendations/Risk Benefit Assessment
`Mifepristone (Korlym) is a glucocorticoid receptor antagonist that is proposed by Corcept
`Therapeutics for the treatment of clinical and metabolic effects of hypercortisolemia in patients
`with endogenous Cushing’s syndrome. Mifepristone is currently marketed in the US by another
`company under the brand name Mifeprex™ for the indication of early termination of pregnancy.
`Corcept submitted this NDA (20705) to the Division under Section 505(b)(2) on April, 2011 .
`The proposed starting dose for Korlym is 300 mg; the dose may be escalated further in 300-mg
`increments to a maximum of 1200 mg once daily based on the assessment of clinical response
`and tolerability.
`
`Currently there is no approved medical therapy to reduce the effects of hypercortisolemia in
`patients with Cushing’s syndrome in the US.
`
`1.1 Recommendation on Regulatory Action
`
`According to my review of clinical data, I recommend approval of the use of Korlym 300 -1200
`mg in patients with Cushing’s syndrome and glucose intolerance or diabetes induced by
`hypercortisolemia.
`
` A
`
` daily administration of Korlym was not effective in producing a clinically meaningful
`improvement of hypertension induced by hypercortisolemia in patients with Cushing’s
`syndrome. Therefore, Korlym should not be recommended for the treatment of hypertension in
`patients with Cushing’s syndrome.
`
`1.2 Risk Benefit Assessment
`
`Korlym (Mifepristone) is a potent and specific antagonist of the type II nuclear glucocorticoid
`receptor (GR-II) and competes with cortisol for the binding to the receptor, preventing the
`biological effect of cortisol. Importantly, it does not decrease cortisol level. Given that the
`Sponsor has demonstrated the drug product’s efficacy and acceptable safety in patients with
`Cushing’s syndrome, Korlym can play a useful role in this population.
`
`Efficacy
`The Sponsor conducted a single Phase 3 pivotal study, Study C1073-400 (referred to as “Study
`400” in this review), in support of the proposed indication. The study was an open label study
`conducted in subjects with clinically significant hypercortisolemia who had not responded
`adequately to surgical or radiation treatment for Cushing's disease, and in subjects with the other
`forms of ACTH-dependent and ACTH-independent endogenous Cushing’s syndrome. An open
`label design was chosen because of the lack of an approved comparator drug. Fifty patients were
`enrolled in the study and received treatment with Korlym for 6 months. The initial dose of
`Korlym was 300 mg orally once a day that was titrated up to 1200 mg once a day based on
`efficacy and safety every 4 weeks or more frequently, if necessary. Patients’ enrollment in the
`
`Reference ID: 3075278
`
`9
`
`(b) (4)
`
`

`

`Clinical Review
`Marina Zemskova, M.D
`NDA 202107
` (Mifepristone Tablets)
`
`
`study was based on the presence of two major complications associated with hypercortisolemia:
`impaired glucose tolerance/diabetes mellitus (the so called “C-DM cohort”) or hypertension (the
`“C-HT cohort”). There was no randomization to the any of these 2 cohorts; patients were
`assigned based on baseline characteristics The study demonstrated that administration of Korlym
`to the 25 subjects in C-DM cohort resulted in a significant improvement in glycemic
`abnormalities: 87% of patients demonstrated an improvement in glycemic control as assessed by
`the percent decrease in the area under the two-hour blood glucose response curve (AUCglucose) at
`the end of the study, and 60% (15/25 subjects) of patients had a reduction in AUCglucose of more
`than 25% (co-primary efficacy endpoint). Because the lower bound of the 1-sided 95%
`confidence interval (CI) was greater than 20% (42%), this response rate of 60% was statistically
`significant. When standard 2-sided 95% CI was applied, the lower CI was 40.4%, still
`statistically significant. The mean change from baseline in AUCglucose was -8722 mg/dL*2hrs (2-
`sided 95% CI = (-13184, -4260), p=0.0009) from a baseline mean of 30670 mg/dL*2hrs. The
`improvement in glycemic control occurred early during the study - at Week 6 visit. Although the
`AUCglucose is not a standard endpoint in the assessment of the glucose control and may be
`affected by the other factors such as diet, exercise, and stress, the improvement in this primary
`efficacy parameter was supported by a significant reduction of HbA1C levels, a secondary
`efficacy endpoint. HbA1C provides a more reliable and validated measure of long-term glycemic
`control. There was a clear improvement in HbA1C by the end of the study: mean values
`decreased by 1.1% (2-sided 95% CI = (-1.56, -0.65), p=0.0001). Of the 12 subjects in the C-DM
`cohort with baseline HbA1C values > 7% (mean 8.5%), nine had reductions in HbA1C values to
`less than 7% at the end of the study. Of these, six subjects had HbA1C values within the normal
`range (< 6%) at the end of the study. Moreover, seven of 19 subjects who were treated with
`antidiabetic medications at baseline had a reduction in the number and/or doses of antidiabetic
`medications by the end of the study; five of 12 subjects who were on insulin therapy had a dose
`reduction of 50% or more by the end of the study. The majority of patients with impaired glucose
`tolerance or diabetes responded to the doses < 600 mg (9 of 15 patients).
`
`Other efficacy findings were supportive of the primary findings of the efficacy of Korlym in the
`cohort of patients with impaired glucose tolerance or diabetes induced by hypercortisolemia.
`Decrease in insulin levels and increase in insulin sensitivity (as evaluated by the homeostatic
`model assessment of insulin resistance (HOMA-IR)), decrease in body weight and waist
`circumference, and improvement in body composition with decrease in total and abdominal fat
`content was consistent with the improvement in glycemic control.
`
`The study met the other primary endpoint and demonstrated that 38% (8/21 subjects) of the
`subjects in C-HT cohort had an improvement in diastolic blood pressure (DBP) by 5 mm Hg or
`more. This result was statistically significant because the lower bound of the one-sided 95% CI
`was greater than 20%, the pre-specified margin of clinical significance. The clinical significance
`of the improvement in blood pressure control in these patients has to be called into question
`because of the following:
`• Hypertension was defined at baseline as systolic blood pressure (SBP) ≥ 140 mmHg and/or
`diastolic blood pressure > 90 mmHg. Thus patients with normal DBP (but elevated SBP)
`
`Reference ID: 3075278
`
`10
`
`(b) (4)
`
`

`

`Clinical Review
`Marina Zemskova, M.D
`NDA 202107
` (Mifepristone Tablets)
`
`
`
`•
`
`were eligible for the study. Further decrease of normal DBP is of unknown clinical
`significance.
`• The median DBP values in all C-HT cohort patients were normal at baseline and decreased at
`the end of the study by 6 mm Hg (from 87 mmHg to 81 mmHg, respectively). The mean
`DBP values did not change at the end of the study as compared to baseline values.
`• The overall improvement in DBP was less striking than improvement in glycemic control:
`only 50% of patients in C-HT had some improvement in DBP. Moreover, the other 50% of
`patients had worsening of DBP control (in contrast only 3 patients (13 %) in C-DM cohort
`had worsening of glycemic control).
`• The Sponsor was advised to apply 95% 2-sided or 97.5% 1-sided confidence intervals. The
`sponsor applied 1-sided CI instead. Thus, biostatistician reviewer computed 95% 2-sided
`confidence interval. The lower bound of the 2-sided 95% confidence interval was 16.8%,
`below the margin, and therefore, not statistically significant.
`• The normalization of DBP only, without SBP control might not be clinically meaningful and
`patients remain hypertensive and carry an overall risk of cardiovascular morbidity and
`mortality.
` Patients in C-HT cohort had multiple protocol violations including incorrect BP
`measurements and initiation or change in doses of antihypertensive medications that might
`affect the blood pressure control at the end of the study. Two of eight patient-responders
`were also treated with spironolactone that was allowed for the treatment of hypokalemia, but
`may also decrease BP.
`• Lastly, cortisol levels remain elevated during treatment with Korlym, and may activate
`mineralocorticoid receptors and increase blood pressure. Thus, the antihypertensive effect of
`Korlym may be less obvious and Korlym may actually worsen BP control.
`
`
`The changes in bone mineral density, in muscle strength, and in cognitive and psychiatric
`function and in quality of life (QOL) were inconclusive, mo

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket